Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma

PURPOSE: PARP-inhibitors have potent radiosensitizing properties in pre-clinical models. To identify the maximum tolerated dose (MTD) of the PARP-inhibitor Olaparib in combination with radiotherapy in patients with head and neck cancer, a single institutional phase-I dose escalation trial was initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Navran, Arash, Al-Mamgani, Abrahim, Elzinga, Hester, Kessels, Rob, Vens, Conchita, Tesselaar, Margot, van den Brekel, Michiel, de Haan, Rosemarie, van Triest, Baukelien, Verheij, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654000/
https://www.ncbi.nlm.nih.gov/pubmed/38021094
http://dx.doi.org/10.1016/j.ctro.2023.100698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654000/
https://www.ncbi.nlm.nih.gov/pubmed/38021094
http://dx.doi.org/10.1016/j.ctro.2023.100698

Ejemplares similares